Journal
BIOMATERIALS
Volume 60, Issue -, Pages 62-71Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2015.04.053
Keywords
Theranostics; WS2; Iron oxide; Mesoporous silica shell; Synergistic therapeutic effect
Funding
- National Basic Research Programs of China (973 Program) [2012CB932600, 2011CB911002]
- National Natural Science Foundation of China [51222203, 51132006]
- Jiangsu Natural Science Fund for Distinguished Young Scholars
- Jiangsu Key Laboratory for Carbon-Based Functional Materials Devices
- Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions
Ask authors/readers for more resources
Integrating multiple imaging and therapy functionalities into one single nanoscale platform has been proposed to be a promising strategy in cancer theranostics. In this work, WS2 nanosheets with their surface pre-adsorbed with iron oxide (IO) nanoparticles via self-assembly are coated with a mesoporous silica shell, on to which polyethylene glycol (PEG) is attached. The obtained WS2-IO@MS-PEG composite nanoparticles exhibit many interesting inherent physical properties, including high near-infrared (NIR) light and X-ray absorbance, as well as strong superparamagnetism. In the mean time, the mesoporous silica shell in WS2-IO@MS-PEG could be loaded with a chemotherapy drug, doxorubicin (DOX), whose intracellular release afterwards may be triggered by NIR-induced photothermal heating for enhanced cancer cell killing. Upon systemic administration of such drug-loaded nano-theranostics, efficient tumor homing of WS2-IO@MS-PEG/DOX is observed in tumor-bearing mice as revealed by three-modal fluorescence, magnetic resonance (MR), and X-ray computed tomography (CT) imaging. In vivo combined photothermal & chemotherapy is then carried out with WS2-IO@MS-PEG/DOX, achieving a remarkably synergistic therapeutic effect superior to the respective mono-therapies. Our study highlights the promise of developing multifunctional nanoscale theranostics based on two-dimensional transition metal dichalcogenides (TMDCs) such as WS2 for multimodal imaging-guided combination therapy of cancer. (C) 2015 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available